60 Degrees Pharmaceuticals to Release Interim Data on Tafenoquine…

Event summary

60 Degrees Pharmaceuticals will release interim data from its hospitalized babesiosis study (NCT06207370) on October 6, 2026.
Key Opinion Leader webinar featuring Dr. Peter Krause and Dr. Edouard Vannier scheduled for the same day.
Tafenoquine, currently approved for malaria prophylaxis, is being evaluated for severe babesiosis treatment.
No FDA-approved treatment exists for babesiosis, highlighting the unmet medical need.

The big picture

60 Degrees Pharmaceuticals is advancing tafenoquine into severe babesiosis, a space with no FDA-approved treatments. The interim data release could validate the drug's potential in a growing vector-borne disease market. The company's strategic focus on repurposing tafenoquine aligns with broader industry trends toward leveraging existing drugs for new indications to address unmet medical needs.

What we're watching

Clinical Efficacy: How the interim data will position tafenoquine against current treatment limitations for severe babesiosis.
Regulatory Pathway: Whether positive data could accelerate FDA approval for tafenoquine in babesiosis.
Market Opportunity: The pace at which 60 Degrees can commercialize tafenoquine for babesiosis if approved.